May 26, 2015
VBL Therapeutics to Webcast Analyst and Investor Event at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2015
TEL AVIV, Israel, May 26, 2015 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a live audio webcast of its discussion of the Company’s clinical programs and pipeline at the ASCO Annual Meeting on Monday, June 1, 2015 at 6:30 a.m. CT (7:30 a.m. ET).
The webcast will be available in the Events and Presentations section under the Investor Relations section of the Company’s website at www.vblrx.com, and an archived replay of the webcast will be available for 30 days after the presentation.
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL has also developed a proprietary platform of small molecules, Lecinoxoids, for the treatment of chronic immune-related indications. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in mid-2015, under a special protocol assessment agreement granted by the FDA.
CONTACT: Hannah Deresiewicz
Stern Investor Relations, Inc.